Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.

Source:http://linkedlifedata.com/resource/pubmed/id/8468720

J. Natl. Cancer Inst. 1993 Apr 21 85 8 622-32

Download in:

View as

Triples

General Info

PMID
8468720